Spero Therapeutics, Inc.
SPRO
Rank in Stocks
#21807
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical... Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$1.07
Last synced: 2026-11-09
Market Cap
$62.31M
Change (1 day)
3.88%
Change (1 year)
-59.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spero Therapeutics, Inc. (SPRO)
Category
Healthcare
EPS for Spero Therapeutics, Inc. (SPRO)
EPS as of June 2026 TTM: $0.14
According to Spero Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $0.14. At the end of 2025 the company had an EPS of $0.15, an increase over its 2024 EPS of $-1.27.
EPS history for Spero Therapeutics, Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.14 | -6.67% |
| 2025 | $0.15 | -111.81% |
| 2024 | $-1.27 | -395.35% |
| 2023 | $0.43 | -134.96% |
| 2022 | $-1.23 | -57.73% |
| 2021 | $-2.91 | -17.33% |
| 2020 | $-3.52 | 6.34% |
| 2019 | $-3.31 | 27.31% |
| 2018 | $-2.60 | -85.41% |
| 2017 | $-17.82 | 361.66% |
| 2016 | $-3.86 | 150.65% |
| 2015 | $-1.54 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 11,085.71% |
US
|
|
| $-7.07 | -5,150.00% |
US
|
|
| $-5.29 | -3,878.57% |
AU
|
|
| $12.88 | 9,100.07% |
BE
|
|
| $21.56 | 15,300.00% |
NL
|
Questions about Spero Therapeutics, Inc.'s earnings per share (EPS)
What is Spero Therapeutics, Inc.'s earnings per share (EPS)?
Spero Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $0.14, as of Jun 2026.
What was Spero Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Spero Therapeutics, Inc.'s earnings per share (EPS) was $0.15, compared with $-1.27 in 2024.
How has Spero Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Spero Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($0.43) and lowest in 2020 ($-3.52).
How does Spero Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Spero Therapeutics, Inc.'s earnings per share (EPS) ($0.14) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.